ACSS3 and prostate carcinoma: Zhou et al. reported that prostate cancer patients with lower ACSS3 expression had significantly shorter DFS in both univariate (HR 0.563, 95% CI 0.36–0.89, p = 0.013) and multivariate analyses (HR 0.575, 95% CI 0.36–0.91, p = 0.018)42.